HomeCompareNLSPW vs QYLD

NLSPW vs QYLD: Dividend Comparison 2026

NLSPW yields 11173.18% · QYLD yields 11.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NLSPW wins by $164653833954869728.00M in total portfolio value
10 years
NLSPW
NLSPW
● Live price
11173.18%
Share price
$0.02
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$164653833954869728.00M
Annual income
$161,805,092,740,060,000,000,000.00
Full NLSPW calculator →
QYLD
Global X Nasdaq 100 Covered Call ETF
● Live price
11.92%
Share price
$17.15
Annual div
$2.04
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.4K
Annual income
$5,659.31
Full QYLD calculator →

Portfolio growth — NLSPW vs QYLD

📍 NLSPW pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNLSPWQYLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NLSPW + QYLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NLSPW pays
QYLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NLSPW
Annual income on $10K today (after 15% tax)
$949,720.67/yr
After 10yr DRIP, annual income (after tax)
$137,534,328,829,050,980,000,000.00/yr
QYLD
Annual income on $10K today (after 15% tax)
$1,013.51/yr
After 10yr DRIP, annual income (after tax)
$4,810.41/yr
At 15% tax rate, NLSPW beats the other by $137,534,328,829,050,980,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NLSPW + QYLD for your $10,000?

NLSPW: 50%QYLD: 50%
100% QYLD50/50100% NLSPW
Portfolio after 10yr
$82326916977434864.00M
Annual income
$80,902,546,370,030,000,000,000.00/yr
Blended yield
98.27%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NLSPW buys
0
QYLD buys
0
No recent congressional trades found for NLSPW or QYLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNLSPWQYLD
Forward yield11173.18%11.92%
Annual dividend / share$2.00$2.04
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$164653833954869728.00M$25.4K
Annual income after 10y$161,805,092,740,060,000,000,000.00$5,659.31
Total dividends collected$164464607760728672.00M$27.1K
Payment frequencyquarterlymonthly
SectorStockETF

Year-by-year: NLSPW vs QYLD ($10,000, DRIP)

YearNLSPW PortfolioNLSPW Income/yrQYLD PortfolioQYLD Income/yrGap
1← crossover$1,128,018$1,117,318.44$10,352$1,192.36+$1.12MNLSPW
2$118,997,241$117,790,261.13$10,830$1,347.57+$118.99MNLSPW
3$11,740,377,185$11,613,050,136.92$11,460$1,539.07+$11740.37MNLSPW
4$1,083,360,524,226$1,070,798,320,638.87$12,275$1,777.84+$1083360.51MNLSPW
5$93,504,509,375,855$92,345,313,614,932.45$13,323$2,078.95+$93504509.36MNLSPW
6$7,548,923,892,561,273$7,448,874,067,529,108.00$14,667$2,463.34+$7548923892.55MNLSPW
7$570,107,151,245,586,050$562,029,802,680,545,500.00$16,396$2,960.57+$570107151245.57MNLSPW
8$40,278,627,085,882,840,000$39,668,612,434,050,070,000.00$18,631$3,612.97+$40278627085882.83MNLSPW
9$2,662,374,967,111,925,000,000$2,619,276,836,130,030,400,000.00$21,548$4,482.15+$2662374967111925.00MNLSPW
10$164,653,833,954,869,740,000,000$161,805,092,740,060,000,000,000.00$25,398$5,659.31+$164653833954869728.00MNLSPW

NLSPW vs QYLD: Complete Analysis 2026

NLSPWStock

NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company also developing NLS-4, a selective dopamine reuptake inhibitor to prevent rare sleep disorders; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist, improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist. NLS Pharmaceutics AG was incorporated in 2015 and is based in Zurich, Switzerland.

Full NLSPW Calculator →

QYLDETF

The Global X Nasdaq 100 Covered Call ETF (QYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe Nasdaq-100 BuyWrite V2 Index.

Full QYLD Calculator →
📬

Get this NLSPW vs QYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NLSPW vs SCHDNLSPW vs JEPINLSPW vs ONLSPW vs KONLSPW vs MAINNLSPW vs XYLDNLSPW vs JEPQNLSPW vs RYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.